Nefes Darlığı ile Acil Servise Başvuran Hastalarda s-TREM’in Konjestif Kalp Yetmezliği ve Pnömoni Ayrımındaki Rolü

Year 2020, Volume: 10 Issue: 3, 233 - 239, 01.12.2020

Ceren Şen Tanrikulu Hilal Hocagil Emine Gencer Ercan Gencer A. Cüneyt Hocagil

Abstract

Amaç: Konjestif kalp yetmezliği (KKY) ve pnömoni acil servise nefes darlığı ile başvuran hastalarda en önemli potansiyel ölüm nedenleridir. Hem KKY hem de pnömonide erken tanı ve uygun müdahale hayat kurtarıcıdır. Bu çalışmanın amacı, pnömoninin CHF’den ayırıcı tanısında inflamatuar bir biyobelirteç olan miyeloid hücreler-1 üzerinde eksprese olan çözünür tetikleyici reseptörün (sTREM-1) tanısal yeteneğini araştırmaktır.
Materyal ve Metot: Bu prospektif çalışma, 1 Haziran 2014 – 30 Mayıs 2015 tarihleri arasında devlet hastanesi ve üniversite hastanelerinin acil tıp bölümlerinde gerçekleştirildi. Dispne ile başvuran hastalar uluslararası kılavuzlara göre yapılan tanılara göre değerlendirildi ve iki gruba ayrıldı; CHF grubu ve pnömoni grubu. Gruplar klinik ve demografik özellikler ve sTREM-1 düzeyleri açısından karşılaştırıldı.
Bulgular: Her grupta 15 hasta değerlendirildi. KKY grubunda nabız hızı daha yüksek iken (p<0,001), pnömoni grubunda solunum hızı ve sıcaklık değerleri daha yüksekti (p=0,002, p=0,008). Akciğer grafilerinde pnömoni grubunda anlamlı infiltrasyon, KKY grubunda kardiyomegali gözlendi (p<0,001). STREM-1 düzeyleri, pnömoni grubunda, CHF grubundan daha yüksekti ve aradaki fark istatistiksel olarak anlamlıydı (p=0,044).
Sonuç: Biz STEM’in acil serviste dispnenin ayırıcı tanısında kuulanılabileceğini, ancak daha kapsamlı çalışmalarla bunun desteklenmesi gerektiğini düşünüyoruz.

Keywords

kronik kalp yetmezliği, pnömoni, sepsis, sTREM-1

References

• 1. Stokes NR, Dietz BW, Liang JJ. Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea. Open Access Emerg Med 2016;8:35-45.
• 2. Michtalik HJ, Yeh HC, Campbell CY, Haq N, Park H, Clarke W, et al. Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. Am J Cardiol 2011;107:1191-5.
• 3. Ferrandis MJ, Ryden I, Lindahl TL, Larsson A. Ruling out cardiac failure: cost-benefit analysis of a sequential testing strategy with NT-proBNP before echocardiography. Ups J Med Sci 2013;118:75-9.
• 4. Januzzi JL Jr, Chen-Tournoux AA, Moe G. Amino-terminal pro- B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol 2008;101:29-38.
• 5. Rosón B, Carratalà J, Dorca J, Casanova A, Manresa F, Gudiol F. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001;33:158-65.
• 6. Schuetz P, Briel M, Mueller B. Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections. JAMA 2013;309:717-8.
• 7. Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 2012;55:651-62.
• 8. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Eur J Heart Fail 2008;10:933-89.
• 9. Aikawa N, Fujishima S, Endo S, Sekine I, Kogawa K, Yamamoto Y, et al. Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother 2005;11:152e9.
• 10. Endo S, Aikawa N, Fujishima S, Sekine I, Kogawa K, Yamamoto Y, et al. Usefulness of procalcitonin serum level for the discrimination of severe sepsis from sepsis: a multicenter prospective study. J Infect Chemother 2008;14:244-9.
• 11. Endo S, Sato N, Suzuki Y, Kojika M, Takahashi G, Yamada Y, et al. Significance of measuring procalcitonin values for diagnosis of sepsis. J Jpn Soc Surg Infect 2007;4:112-20.
• 12. Mulrow C, Lucey C, Farnett L. Discriminating causes of dyspnea through the clinical examination. J Gen Intern Med 1993;8:383-92.
• 13. Yurchyak PM. Cardiac problems in the pulmonary patient. Fishman AP, ed. Pulmonary Diseases and Disorders, 2nd ed. New York, NY: McGraw-Hill; 1988.
• 14. Deveraux RB, Liebson PR, Horan MJ. Recommendations concerning use of echocardiography in hypertension and general population research. Hypertension 1987;9:97-104.
• 15. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002;39:202-9.
• 16. Hartupee J, Mann DL. Positioning of inflammatory biomarkers in the heart failure landscape. J Cardiovasc Transl Res 2013;6:485-92.
• 17. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines . Circulation. 2005;112:154-235.
• 18. Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in CHF. Ann Emerg Med 1992;21:669-74.
• 19. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. The New England Journal of Medicine 1990;323:236-41.
• 20. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of b-type natriuretic peptide (BNP) in the diagnosis of CHF in an urgent care setting. J Am Coll Cardiol 2001;37:379-85.
• 21. Chalmers JD, Singanayagam A, Akram AR, Mandal P, Short PM, Choudhury G, et al. Severity assessment tools for predicting mortality in hospitalised patients with communityacquired pneumonia. Systematic review and meta-analysis. Thorax 2010;65:878-83.
• 22. Richards G, Levy H, Laterre PF, Feldman C, Woodward B, Bates BM, et al. CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS. J Intensive Care Med 2011;26:34-40.
• 23. Schuetz P, Wolbers M, Christ-Crain M, Thomann R, Falconnier C, Widmer I, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care 2010;14:R106.
• 24. Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T. Cardiovascular and inflammatory biomarkers to predict shortand longterm survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010;182:1426-34.
• 25. Pierrakos C, Vincent JL: Sepsis biomarkers: a review. Crit Care 2010;14:R15.
• 26. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and mono-cytes. J Immunol 2000;164:4991-5.
• 27. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004;350:451-8. 28. Zhang J, She D, Feng D, Jia Y, Xie L. Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study. BMC Infect Dis 2011;11:53.
• 29. Ramirez P, Kot P, Marti V, Gomez MD, Martinez R, Saiz V, et al. Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in patients with acute respiratory distress syndrome and abdominal diseases: a preliminary observational study. Crit Care 2011;15:R50.